When Lucas received a diagnosis of a rare brain tumor at six, the prognosis was grim, and Dr. Jacques Grill of the Gustave Roussy Cancer Center in Paris emotionally conveyed the dire news to Lucas's parents. Nevertheless, seven years later, now 13, Lucas stands as the world's first child cured of brainstem glioma, a brutal cancer, defying all odds.
The three treatment plans in chronological order (from top to bottom) with representative slides (a,d,g sagittal; b,e,h axial; c,f,i frontal). Color-wash depiction of 95% of the prescription dose. The lateral cold spot in b was accepted with regard to cochlear sparing
DIPG: Progress, Survival, Urgent Need for Research
Lucas suffers from a rare brain tumor called diffuse intrinsic pontine glioma (DIPG), which is an aggressive brain tumor occurring in the pons, a critical part of the brainstem governing functions such as breathing, heartbeat, and muscle control.
Affecting approximately 300 children annually, predominantly those aged 5-9, DIPG poses significant challenges as it exerts pressure on various brain regions, impacting nerves controlling facial sensation and muscle function.
Despite overall childhood cancer survival improving to 85%, there's no DIPG cure, and most children don't survive a year post-diagnosis. Radiotherapy temporarily slows the tumor, but effective drugs are lacking, driving ongoing research for innovative treatments.
As International Childhood Cancer Day nears, progress in treating childhood cancers is celebrated, with an 85% five-year survival rate for most cases. Yet, the challenging scenario persists for DIPG, where only about 10% survive two years post-diagnosis. Although radiotherapy has limited success, the absence of effective drugs emphasizes the urgent need for innovative research to enhance outcomes for children battling DIPG.
READ ALSO: Two Cancer-Stricken Children in Japan Got Their Tumor Cells Before Birth
Lucas' DIPG Triumph Ignites Hope Worldwide
Lucas and his family made a journey from Belgium to France to participate in the BIOMEDE trial, where he became one of the initial patients testing potential new drugs for DIPG.
Assigned to the cancer drug Everolimus, Lucas exhibited a robust response, with his tumor entirely disappearing over a series of MRI scans, an unprecedented outcome as reported by Dr. Grill. However, the cautious approach led the doctor to continue the treatment until Lucas revealed, a year and a half ago, that he had ceased taking the drugs independently.
Dr. Grill expressed astonishment at Lucas's unique case, emphasizing its singularity globally. The mystery behind Lucas's complete recovery and its potential implications for other children with DIPG remain to be unraveled. While seven other children in the trial survived for years, only Lucas's tumor vanished entirely.
Dr. Grill attributes the varying responses to the drugs to the "biological particularities" of individual tumors, pointing out Lucas's tumor's extremely rare mutation, making its cells unusually sensitive to the drug.
Researchers aim to replicate Lucas's genetic differences in lab-created tumor "organoids" for potential eradication. If successful, the next step involves identifying a drug with a similar impact, but researchers caution that transitioning from discovery to treatment is time-consuming.
Despite the promising path, the researchers emphasize the considerable time involved in developing an actual drug, cautioning that any potential treatment is still years away.
Pediatric oncologists globally express optimism about curing some DIPG patients, citing advancements, funding, and trials like BIOMEDE. They acknowledge significant progress and express confidence in the possibility of curing some patients in the foreseeable future.
RELATED ARTICLE: Tumor Developed From Eye Squint? 8-Year-Old Boy Diagnosed with Rare Incurable Cancer of the Brain After Strabismus
Check out more news and information on Cancer in Science Times.
